Pillar-like molecules as biosensors for metabolites

January 11, 2021

Metabolites are organic molecules that take part in or are created during the biochemical reactions constantly taking place in an organism. For the human body, more than 110,000 metabolites have been identified. Metabolites play a role in metabolic syndrome, which is the situation in which several medical conditions occur simultaneously; the conditions include obesity, high blood pressure and high blood sugar. Metabolic syndrome is associated with a higher risk of developing cardiovascular disease, type-2 diabetes and different kinds of cancer. The presence of certain metabolites can be an indicator for particular pathological conditions related to metabolic syndrome. Efficiently measuring and monitoring the presence is therefore important for early diagnosis. Now, Tomoki Ogoshi*, Atsushi Hirao*, and Masaya Ueno (*correspondence authors) from Kanazawa University and colleagues have developed a biosensor for a low-molecular-weight metabolite known as 1-MNA. The sensor relies on the physicochemical properties of pillar[6]arene, a channel-like molecule.

The researchers investigated the metabolite 1-MNA (1-methylnicotinamide), recently discovered to be present in higher levels in aggressive cancer cell lines. These cancers have increased NNMT (nicotinamide N-methyltransferase) activity in which 1-MNA is a byproduct. Detecting 1-MNA could be therefore crucial for the timely diagnosis and treatment of such cancers.

Ogoshi and colleagues hypothesized that pillar[n]arenes could be used as biosensors for metabolites like 1-MNA. Pillar[n]arenes are pillar-shaped macrocyclic compounds with a polygonal cross-section (pentagonal and hexagonal for n = 5 and 6, respectively). The researchers found that pillar[6]arene (P6A) forms host-guest a complex with 1-MNA; the metabolite can bind to it because the hexagonal cavity inside P6A offers just the right environment for doing so. They also found that when 1-MNA is bound to P6A, the fluorescent response of the latter significantly decreases -- an effect that can be exploited as an indicator for the presence or absence of 1-MNA (strong or weak fluorescent response, respectively).

Importantly, the scientists could show that the P6A fluorescence detection mechanism works for biological samples. Specifically, they were able to detect 1-MNA in urine, albeit with a low sensitivity. Ogoshi and colleagues conclude that additional experiments "will help to improve the sensitivity and specificity of the biosensors", and that their work "should contribute to the development of low-cost, easy, and rapid methods for the detection of human metabolites for diagnosis".

[Background]

Metabolic syndrome

Metabolic syndrome refers to the combination of diabetes, high blood pressure (hypertension) and obesity. Patients with metabolic syndrome are at a greater risk for developing certain cardiovascular diseases as well as different types of cancer. Metabolic syndrome is often associated with being overweight and a lack of physical activity, and is also linked to insulin resistance (a key feature of type-2 diabetes).

Now, Tomoki Ogoshi from Kanazawa University and colleagues have developed a biosensor for a metabolite known as 1-MNA. Being able to efficiently detect metabolites associated with certain pathologies is an important step forward towards the development of treatments for pathologies associated with metabolic syndrome.

Pillar[n]arenes

Pillar[n]arenes, collectively named pillararenes (and sometimes pillarenes), are cyclic organic molecules consisting of n so-called hydroquinone units, which can be substituted. Hydroquinone, also known as quinol, has the chemical formula C6H4(OH)2. It consists of a benzene ring with two hydroxyl (OH) groups bound to it at opposite sides of the benzene hexagon.

The first pillararene was synthesized in 2008 by Tomoki Ogoshi and colleagues from Kanazawa University. The name pillararene was chosen since the molecules are cylindrical (pillar-like) in shape and composed of aromatic moieties (arenes).

Now, Ogoshi, Hirao and colleagues have shown that pillar[6]arene (n = 6) can be used as biosensors for the metabolite 1-MNA -- an important result given that detecting low-molecular-weight metabolites is challenging.
-end-


Kanazawa University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.